MLTX
MoonLake Immunotherapeutics
$14.79
+$0.72(+5.12%)
54
Overall
60
Value
54
Tech
50
Quality
Market Cap
$672.08M
Volume
2.51M
52W Range
$5.95 - $62.75
Target Price
$14.61
Company Overview
| Mkt Cap | $672.08M | Price | $14.79 |
| Volume | 2.51M | Change | +5.12% |
| P/E Ratio | -5.7 | Open | $14.24 |
| Revenue | -- | Prev Close | $14.07 |
| Net Income | $-118.9M | 52W Range | $5.95 - $62.75 |
| Div Yield | N/A | Target | $14.61 |
| Overall | 54 | Value | 60 |
| Quality | 50 | Technical | 54 |
No chart data available
About MoonLake Immunotherapeutics
MoonLake Immunotherapeutics, a clinical stage biopharmaceutical company, engages in developing therapies. The company develops Sonelokimab, a novel tri-specific investigational Nanobody for the treatment of inflammation diseases; and hidradenitis suppurativa, psoriatic arthritis, axial spondyloarthritis, and psoriasis. MoonLake Immunotherapeutics was founded in 2021 and is headquartered in Zug, Switzerland.
| A | B | C | D | |
|---|---|---|---|---|
| 1 | Symbol | Price | Change | Vol |
| 2 | MLTX | $14.79 | +5.1% | 2.51M |
| 3 | ||||
| 4 | ||||
| 5 | ||||
| 6 |
Get MoonLake Immunotherapeutics Data in Excel
Stream real-time data directly to your spreadsheets
BUY NOW